Neurology Specific Literature Search   

(Click to cross reference)
adverse drug reaction
anticoagulant, treatment
anticoagulant, treatment in CVD
atrial fibrillation
atrial fibrillation, risk stratification
cerebrovascular accident, prevention of
dabigatran, dose
HAS-BLED score
INR value, time in range
INR values
intracerebral hemorrhage
practice guidelines
prevention of neurologic disorders
RELY trial
review article
treatment of neurologic disorder
Showing articles 0 to 50 of 104 Next >>

Progress for Stroke Prevention with Atrial Fibrillation
Stroke 43:1179-1185, Katsnelson,M.,et al, 2012

Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010

Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010

Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke
Stroke 51:1616-1619, Beharry, J.,et al, 2020

Stroke Reperfusion Therapy Following Dabigatran Reversal with Idarucizumab in a National Cohort
Neurol 94:e1968-e1972, Barber, P.A.,et al, 2020

Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019

Management of Bleeding in Patients Taking Oral Anticoagulants
JAMA 319:2032-2033, Anderson, I.,et al, 2018

Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018

Improved Stroke Prevention in Atrial Fibrillation after the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 49:2122-2128, Forslund, T.,et al, 2018

Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy
JAMA 320:1485-1486, Sholzberg, M. & Xu, Y., 2018

Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017

NEJM 377:553-561, Charles, A., 2017

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
NEJM 377:431-441, Pollack, C.V.,et al, 2017

Low-Dose Aspirin and Risk of Intracranial Bleeds
Neurol 89:2280-2287, Soriano, L.C.,et al, 2017

Leakage Sign for Primary Intracerebral Hemorrhage
Stroke 47:958-963, Orito, K.,et al, 2016

Which Oral Anticoagulation for Atrial Fibrillation?
JAMA 315:2117-2118, The Medical Letter, 2016

Risk of Gastrointestinal Bleeding Associated with Oral Anticoagulants: Population Based Retrospective Cohort Study
BMJ 350:h1585, h1679, Chang, H.Y.,et al, 2015

Comparative Risk of Gastrointestinal Bleeding with Dabigatran, Rivaroxaban, and Warfarin: Population Based Cohort Study
BMJ 350:h1857, h1979, Abraham, N.S.,et al, 2015

Idarucizumab for Dabigatran Reversal
NEJM 373:511-520, Pollack, C.V.,et al, 2015

A 73-year-old Man with Diplopia and Ataxia
Neurol 85:e96-e100, Gupta, H.V.,et al, 2015

FDA Approves Praxbind, the First Reversal Agent for the Anticoagulant Pradaxa
JAMA 314:2227, , 2015

Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014

Rethinking Warfarin for Atrial Fibrillation
JAMA 311:1246, Zuccott, G & Pflomm, J.M., 2014

Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated with Dabigatran or Warfarin
Stroke 45:2286-2291, Alonso, A.,et al, 2014

Oral Anticoagulants and the Risk of Intracranial Hemorrhage
JAMA 312:2562-2563, Vespa, P.M., 2014

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013

Intracraial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation with Warfarin or Dabigatran
Stroke 43:1511-1517, Hart, R.G.,et al, 2012

High-Dose Statins should be Used in All Acute Ischemic Strokes
Stroke 43:1992-1993, 1996, Moonis, M., 2012

High-Dose Statins Should Only Be Used in Atherosclerotic Strokes
Stroke 43:1994-1995,1996, Furie, K.L., 2012

Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012

Nonvitamin K-Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack
Stroke 43:3298-3304, Ntaios, G.,et al, 2012

Efficacy and Safety of Ketamine in Refractory Status Epilepticus in Children
Neurol 79:2355-2358, Rosati, A.,et al, 2012

Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012

New Antithrombotic Drugs for Atrial Fibrillation: Caution is Needed
Lancet 379:e24, Bell,S.,et al, 2012

Anticoagulant Loses its Lustre
Lancet 379:301, Mullar,A., 2012

Intramuscular Versus Intravenous Therapy for Prehospital Status Epilepticus
NEJM 366:591-600,659, Silbergleit,R.,et al, 2012

Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012

Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011

Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy
NEJM 365:285-287, Egan, A.,et al, 2011

Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011

Acutely Injured Patients on Dabigatran
NEJM 365:2039-2040, Cotton, B.A.,et al, 2011

Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010

Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison With Double-Dose Gadopentetate Dimeglumine
AJNR 31:1055-1058, Kim,E.S., et al, 2010

The Use of Platelet Function Assays May Help to Determine Appropriate Antiplatelet Treatment Options in a Patient With Recurrent Stroke on Baby Aspirin: Against
Stroke 41:2398-2399, 2400, Eikelboom,J.W.,et al, 2010

Platelet Function Assays in Stroke Management: More Study is Needed
Stroke 41:2396-2397, 2400, Selim,M.H.,et al, 2010

Dabigatran Etexilate - A Novel, Reversible, Oral Direct Thrombin Inhibitor: Interpretation of Coagulation Assays and Reversal of Anticoagulant Activity
Thromb Hemost 103:1116-1127, van Ryn,J.,et al, 2010

Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009

Tolerability and Efficacy of Oral Loading of Leviteracetam
Neurol 70:2166-2170, Koubeissi,M.Z.,et al, 2008

Showing articles 0 to 50 of 104 Next >>